Literature DB >> 27373773

Transparency in drug regulation: public assessment reports in Europe and Australia.

Peter Papathanasiou1, Laurent Brassart2, Paul Blake2, Anna Hart3, Lel Whitbread3, Richard Pembrey3, Jill Kieffer4.   

Abstract

Openness and transparency are important considerations for medicines regulators, where public health is of paramount concern. As part of their commitment to transparency, the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA) in Australia publish information relating to their evaluation of medicines via public assessment reports. European Public Assessment Reports (EPARs) and Australian Public Assessment Reports (AusPARs) provide information about the considerations that led the regulator to approve or refuse the application. The reports summarise assessments by each regulator of the information provided on the quality, safety, and efficacy of the medicine under evaluation. Here, we describe the experiences of two established medicines regulators in publishing public assessment reports, and reflect on their future role in communicating medicines information.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27373773     DOI: 10.1016/j.drudis.2016.06.025

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

2.  Dosing antibiotics in neonates: review of the pharmacokinetic data.

Authors:  Nazario D Rivera-Chaparro; Michael Cohen-Wolkowiez; Rachel G Greenberg
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.553

3.  Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.

Authors:  Ali M Alsamil; Thijs J Giezen; Toine C Egberts; Hubert G Leufkens; Helga Gardarsdottir
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

4.  Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community.

Authors:  L A Minnema; T J Giezen; T C G Egberts; H G M Leufkens; H Gardarsdottir
Journal:  Eur J Neurol       Date:  2020-05-10       Impact factor: 6.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.